SAN MATEO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that the previously signed binding Term Sheet between Vincerx, Oqory, Inc., and Vivasor, Inc. for a reverse merger transaction has been terminated.

Original post:
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives

EMERYVILLE, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported full year 2024 financial results, provided operational highlights and outlined expected upcoming milestones.

More here:
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate at the following healthcare conferences:

Continue reading here:
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

A heart disease trigger that lurks inside bone marrow  Harvard Health

Read more here:
A heart disease trigger that lurks inside bone marrow - Harvard Health

Four-year-old donates stem cells to save her baby sister from blood cancer in Odisha  The Hindu

Follow this link:
Four-year-old donates stem cells to save her baby sister from blood cancer in Odisha - The Hindu

Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCT  Nature.com

More here:
Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a...

KU Cancer Center recognized for transplant that saved 1-year-olds life  WDAF FOX4 Kansas City

Excerpt from:
KU Cancer Center recognized for transplant that saved 1-year-olds life - WDAF FOX4 Kansas City

4-year-old donates stem cells to save sister as SCB performs first-of-a-kind bone marrow transplant in Odisha  OTV News

See the article here:
4-year-old donates stem cells to save sister as SCB performs first-of-a-kind bone marrow transplant in Odisha - OTV News

Orca-T With RIC Is Safe in Advanced Hematologic Malignancies  OncLive

More here:
Orca-T With RIC Is Safe in Advanced Hematologic Malignancies - OncLive

Bahrain's pioneering use of sickle cell disease treatment hailed by medical experts  The National

Here is the original post:
Bahrain's pioneering use of sickle cell disease treatment hailed by medical experts - The National

SCB conducts Odisha's first bone marrow transplant on two-year-old  The New Indian Express

Originally posted here:
SCB conducts Odisha's first bone marrow transplant on two-year-old - The New Indian Express

Media ReleaseCOPENHAGEN, Denmark; February 19, 2025Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano and Chief Development Officer Judith Klimovsky will participate in a fireside chat at the 45th Annual TD Cowen Health Care Conference in Boston, Massachusetts at 1:50 PM EST (7:50 PM CET) on March 3, 2025.?A webcast of the fireside chat will be available on Genmab’s website at https://ir.genmab.com/events-presentations.

Read more from the original source:
Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference

SARASOTA, Fla. and MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today announced that its board of directors has nominated five new candidates with extensive experience in in the biotechnology industry to be approved at the company shareholder meeting scheduled for March 10th, 2025.

Here is the original post:
NAYA Biosciences Announces Nomination of New Board Members

Leading clinician and researcher in Pulmonary Disease Therapeutics Leading clinician and researcher in Pulmonary Disease Therapeutics

See the original post here:
OrphAI Therapeutics Announces Appointment of Dr. Aaron Waxman to Board of Directors

Groundbreaking Study Demonstrates Safety and Tolerability of Oral Mucosal Immunotherapy (OMIT) for Peanut Allergy Using Toothpaste Groundbreaking Study Demonstrates Safety and Tolerability of Oral Mucosal Immunotherapy (OMIT) for Peanut Allergy Using Toothpaste

Follow this link:
Intrommune Therapeutics Announces Publication of OMEGA Study in Peanut Allergic Adults in Annals of Allergy, Asthma & Immunology

Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers

Read more here:
Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers

BOSTON, Massachusetts, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ("Radiance" or the "Company"), a biotechnology company, today announced that it has entered into an exclusive License agreement with CSPC Megalith Biopharmaceutical Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093) for development and commercialization of RB-164 (SYS6005): a novel clinical stage antibody drug conjugate (ADC) targeting ROR-1. The agreement covers exclusive commercialization rights to RB-164 in the United States of America (USA), Canada, the European Union, the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, and Australia. CSPC will retain all rights to SYS6005 in the remaining global markets.

View original post here:
Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate

TAMPA, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, announced today that it convened its special meeting (“Special Meeting”) and immediately adjourned the meeting, with conducting any business, to March 21, 2025. The Special Meeting was adjourned as to all of the proposals contained in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (“SEC”) on January 28, 2025 (the “Proxy Statement”), including the proposal to approve the arrangement transaction with SRx Health Solutions, Inc. (“SRx”).   The Company adjourned the Special Meeting to allow SRx to continue to pursue its shareholder vote and the final order by the Ontario Superior Court of Justice required to consummate the arrangement transaction and to update Better Choice shareholders of certain corporate actions to be taken by SRx and the Company to ensure compliance with the NYSE American listing requirements.

Go here to see the original:
Better Choice Company Adjourns Special Meeting of Stockholders to March 21, 2025

This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage’s 5,500 advertisers and 55,000 publishers, creating one of the most expansive and effective affiliate networks in the industry This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage’s 5,500 advertisers and 55,000 publishers, creating one of the most expansive and effective affiliate networks in the industry

Excerpt from:
COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing

TORONTO and HAIFA, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is proud to announce its inclusion in the 2025 TSX Venture 50™, a prestigious annual ranking of the top-performing companies on the TSX Venture Exchange (“TSXV”). NurExone is honored to be the only biotech company, and one of three life sciences companies, to receive this designation, highlighting NurExone’s leadership in the emerging field of exosome-based therapies and regenerative medicine for central nervous system injuries. This recognition also highlights NurExone’s strong market performance and strategic advances in the past year including 110% share price appreciation and 209% market cap growth.

Read the original here:
NurExone Biologic Recognized as a 2025 TSX Venture 50™ Top Performing Stock